Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body
AssigneesPfizer Inc., Iteos Therapeutics
InventorsManfred Kraus, Sandra Cauwenberghs, Stefano Crosignani, Gregory Driessens
Life of this patent
Estimating the term…
Abstract
Combinations of an IDO1 inhibitor (e.g., a 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione compound), with an anti-PD1 antibody or anti-PD-L1 antibody, and an anti-4-1BB antibody, as selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for the treatment and/or prevention of cancer and endometriosis.
Claims26
A combination regimen useful in cancer treatment comprising the co-administration to a subject in need thereof of (a) at least one indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, (b) at least one second active component which is an immunomodulatory agent selected from an anti-PD-1 or anti-PD-L1 antibody, and (c) at least a third active component which is an anti-4-1BB antibody, wherein the IDO1 inhibitor is a racemic 3-(5-fluoro -1H-indol-3-yl) pyrrolidine-2,5-dione, the (R)- enantiomer thereof, the (S)-enantiomer thereof, or a mixture thereof.
Dependencies are inferred from the claim text.